article · Journal of Rare Diseases
Human metapneumovirus has re-emerged as a major public health concern following a surge in global cases that began in late 2024. First reported in China and spreading to countries including the United States, India, and Pakistan, the virus poses severe risks to young children, the elderly, and immunocompromised patients. Data shows a seventeen percent rise in paediatric hospital admissions related to the virus in early 2025 compared to early 2023. The virus evades host defences by suppressing interferon signalling and critical antiviral cytokines, allowing prolonged replication while triggering excessive pro-inflammatory responses that damage tissue. Impaired dendritic cell activation, suboptimal T-cell responses, and a high mutation rate limit durable immunity and heighten pathogenicity. Mitigating this threat requires improved genomic surveillance, novel vaccine candidates, monoclonal antibody therapies, and host-directed treatments.
A recent rise in human metapneumovirus infections presents a growing risk of severe respiratory illness, particularly for vulnerable groups such as children, the elderly, and immunocompromised patients. Because the virus effectively evades immune defences and causes tissue-damaging inflammation, understanding its biology is vital for healthcare systems preparing better monitoring, diagnostics, and medical treatments against potential future outbreaks.
The findings outline targets for the biopharmaceutical and diagnostics sectors, focusing on early-stage opportunities in genomic surveillance tools, novel vaccine candidates, monoclonal antibody therapies, and host-directed immunomodulatory treatments. The abstract presents a review of viral mechanisms and epidemiological trends rather than tested interventions, indicating these therapeutic and preventive approaches remain at an early, exploratory stage of research.
AI-generated from the published abstract. Always read the original work before citing.
Abstract Human metapneumovirus (hMPV), a prominent respiratory pathogen with a history of global circulation spanning over seven decades, has re-emerged as a critical public health concern. Since late 2024, there has been a significant global surge in hMPV cases, first reported in China and subsequently spreading to countries such as the USA, India, and Pakistan. Although the World Health Organization (WHO) and Chinese authorities have downplayed the severity of this increase, attributing it to expected seasonal trends, the growing prevalence of hMPV raises alarm due to its potential to cause severe respiratory illness. Particularly at risk are vulnerable populations, including children, the elderly, and immunocompromised individuals. Recent epidemiological data indicate a 17% increase in pediatric hMPV-related hospital admissions in the first quarter of 2025 compared to the same period in 2023 in both the USA and China, with similar trends observed among elderly and immunocompromised patients. These findings highlight the urgent need for enhanced surveillance and public health preparedness. This study explores the immunopathogenesis of hMPV, which is marked by its immune evasion strategies, including inhibition of interferon signaling pathways and suppression of key antiviral cytokines. These mechanisms enable persistent viral replication and contribute to severe respiratory pathologies. Moreover, dysregulated cytokine production, particularly the overexpression of pro-inflammatory cytokines, exacerbates immune responses and leads to tissue damage, further worsening clinical outcomes in vulnerable populations. This review delves into the complex immune dynamics of hMPV infection, highlighting impaired dendritic cell activation and suboptimal T-cell responses, which hinder long-lasting immunity, especially in immunocompromised individuals. The virus's high mutation rate (6.95 to 7.12 × 10 −4 substitutions/site/year), along with its immune evasion mechanisms and significant cytopathic effects, further enhances its pathogenicity. The global spread of hMPV underscores its resilience and adaptability, making it a growing threat to public health. As hMPV-related immunology becomes increasingly relevant amid this new outbreak, this review emphasizes the need for robust genomic surveillance, targeted antiviral therapies, and vaccine development. Drawing on lessons from COVID-19 and Ebola, the importance of early detection systems, antiviral research, and targeted immunization strategies is paramount to mitigating the impact of this emerging viral threat. With insights from the current study, future immunological approaches should prioritize the development of novel vaccine candidates, enhancement of monoclonal antibody therapies, and improvement of host-directed immunomodulatory treatments. By integrating these strategies, global health systems can effectively respond to future hMPV outbreaks and safeguard vulnerable populations.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.1007/s44162-025-00079-w
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.
